BRC 003
Alternative Names: BRC 003 CBD; BRC-003Latest Information Update: 06 Dec 2024
Price :
$50 *
At a glance
- Originator Biopharmaceutical Research Company
- Class Antiepileptic drugs; Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Epilepsy
Most Recent Events
- 19 Nov 2024 Phase-II clinical trials in Epilepsy (Treatment-resistant) in USA (PO) (NCT06523725)
- 02 Aug 2024 Preclinical trials in Epilepsy in USA (PO)
- 26 Jul 2024 Biopharmaceutical Research Company plans a phase II trial for Epilepsy (Refractory) (PO) in August 2024 (NCT06523725)